massively parallel sequencing
Illumina, Tempus AI Collaborate on Generating Evidence for Clinical NGS-Based Testing
The companies plan to combine Tempus' multimodal data platform and Illumina's AI-driven molecular analysis technologies.
Dovetail Genomics, CareDx Partner on HLA Genotyping for Transplant Matching
The firms will launch an early-access program for CareDx's NGS-based AlloSeq Tx 17 HLA typing assay, which incorporates Dovetail's LinkPrep NGS technology.
Pillar Biosciences, AstraZeneca Partner on Liquid Biopsy Testing in Europe
AstraZeneca has partnered with several other firms on liquid biopsies, including Angle, Sophia Genetics, IMBdx, and Guardant Health.
Illumina, Devyser Diagnostics Ink IVD Development Agreement
The agreement will enable Sweden's Devyser to perform regulatory registrations of its NGS-based IVD tests on Illumina's MiSeqDx sequencer in the US and Europe.
A comparison for 144 solid tumor samples showed a "high degree of alignment" with FoundationOne CDx and better calling of CNAs than Illumina's TSO 500.
Oct 12, 2023
European Commission Orders Illumina to Divest Grail
Mar 30, 2021
FTC Moves to Block Illumina's $8B Grail Acquisition
Feb 25, 2021
Feb 24, 2021